-+ 0.00%
-+ 0.00%
-+ 0.00%

Evotec Presents Plan Targeting EUR 75 Million in Annual Run-Rate Cost Savings by End-2027

PUBT·11/06/2026 19:35:21
Listen to the news
Evotec Presents Plan Targeting EUR 75 Million in Annual Run-Rate Cost Savings by End-2027
  • Evotec signed a deal to sell its Toulouse biologics site to Sandoz for approximately US$ 350 million upfront, including technology licensing.
  • The agreement includes more than US$ 300 million in license, milestone and development revenue commitments for 2026-2028.
  • Royalties on 10 biosimilars offer additional revenue potential beyond 2028; six are in technical development.
  • The Horizon restructuring targets approximately 800 job cuts, reducing the global footprint from 14 sites to 10.
  • Expected annual run-rate savings reach approximately EUR 75 million by end-2027, against approximately EUR 100 million in total cash costs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.